Investigating Immune-Microbiome interactions during treatment of Clostridioides difficile with fecal microbiome transplantation

研究粪便微生物组移植治疗艰难梭菌期间免疫-微生物组的相互作用

基本信息

  • 批准号:
    10185169
  • 负责人:
  • 金额:
    $ 47.43万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-02-05 至 2026-01-31
  • 项目状态:
    未结题

项目摘要

Project Summary Hospitalized patients receiving antibiotic treatment experience a disruption in the intestinal microbiome enabling opportunistic pathogens, such as Clostridioides difficile to colonize the intestinal tract. Complications resulting from C. difficile associated disease are a major burden on the health care system costing an estimated one billion dollars and resulting in 12,000-20,000 deaths per year (11, 13). Current antibiotic treatment options have a high recurrence rate highlighting the need to develop alternative treatment strategies. Fecal microbiome transplantation (FMT) has proven to be a remarkable effective strategy for treatment of recurrent C. difficile infection (21). However, the host and microbial factors that contribute to FMT success remain poorly defined. The murine model of C. difficile infection offers insights into the mechanism of action of FMT. Data presented in this proposal demonstrates an important role for the host’s immune system, specifically CD4+ T-regulatory (TReg) cells, in supporting FMT efficacy. In aim 1 of this proposal we will investigate the immunoregulatory mechanisms through which TReg cells shape the intestinal environment to promote FMT engraftment and C. difficile resolution. Conversely, aim 2, will assess the innate immune inflammatory mediators that shape the intestinal environment to inhibit FMT engraftment and C. difficile resolution. In parallel to murine studies, we will conduct longitudinal profiling of human immune cell populations in severe C. difficile infected patients before and after FMT. These aims will identify immune mechanisms that support successful FMT therapy in C. difficile infection and potentially identify novel therapeutic targets in treating C. difficile associated disease. 1
项目摘要 接受抗生素治疗的住院患者经历肠道微生物组的破坏 使机会致病菌如艰难梭菌在肠道定植。并发症 由C.艰难梭菌相关疾病是卫生保健系统的主要负担, 估计10亿美元,每年造成12,000 - 20,000人死亡(11,13)。当前抗生素 治疗方案的复发率很高,这突出表明需要开发替代治疗策略。 粪便微生物组移植(FMT)已被证明是治疗肠道疾病的一种非常有效的策略。 复发C.艰难梭菌感染(21)。然而,有助于FMT成功的宿主和微生物因素 定义不明确。小鼠C.艰难梭菌感染提供了深入了解的作用机制, FMT。本提案中提出的数据表明了宿主免疫系统的重要作用, 特别是CD 4 + T调节(TReg)细胞,以支持FMT功效。在本提案的目标1中,我们将 研究TReg细胞塑造肠道环境的免疫调节机制, 促进FMT植入;艰难的决议。相反,目标2,将评估先天免疫 影响肠道环境以抑制FMT植入的炎症介质和C.艰难 分辨率在小鼠研究的同时,我们将对人类免疫细胞群进行纵向分析 严重C. FMT前后的艰难梭菌感染患者。这些目标将确定免疫机制, 支持成功的FMT治疗C。艰难梭菌感染,并可能确定新的治疗靶点, 治疗C.艰难梭菌相关疾病 1

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael C. Abt其他文献

Standard mouse diets lead to differences in severity in infectious and non-infectious colitis
标准小鼠饮食导致感染性和非感染性结肠炎严重程度的差异
  • DOI:
    10.1128/mbio.03302-24
  • 发表时间:
    2025-02-25
  • 期刊:
  • 影响因子:
    4.700
  • 作者:
    Joshua E. Denny;Julia N. Flores;Nontokozo V. Mdluli;Michael C. Abt
  • 通讯作者:
    Michael C. Abt
Monocyte Reconstitution and Gut Microbiota Composition after Hematopoietic Stem Cell Transplantation
造血干细胞移植后的单核细胞重建和肠道菌群组成
  • DOI:
    10.1101/777268
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    0
  • 作者:
    S. Morjaria;Allen W. Zhang;Sohn G. Kim;J. Peled;Simone Becattini;E. Littmann;E. Pamer;M. Perales;Michael C. Abt
  • 通讯作者:
    Michael C. Abt
Therapeutic activation of IL-22-producing innate lymphoid cells enhances host defenses to emClostridioides difficile/em infection
产生白细胞介素-22 的先天淋巴细胞的治疗性激活增强了宿主对艰难梭菌感染的防御能力。
  • DOI:
    10.1016/j.celrep.2025.115438
  • 发表时间:
    2025-04-22
  • 期刊:
  • 影响因子:
    6.900
  • 作者:
    Kevin S. Mears;Joshua E. Denny;Jeffrey R. Maslanka;Nontokozo V. Mdluli;Ellie N. Hulit;Rina Matsuda;Emma E. Furth;Charlie G. Buffie;Michael C. Abt
  • 通讯作者:
    Michael C. Abt
Antigen-specific memory Th17 cells promote cross-protection against nontypeable emHaemophilus influenzae/em after mild influenza A virus infection
抗原特异性记忆 Th17 细胞促进轻度甲型流感病毒感染后对非分型流感嗜血杆菌的交叉保护
  • DOI:
    10.1016/j.mucimm.2023.01.007
  • 发表时间:
    2023-04-01
  • 期刊:
  • 影响因子:
    7.600
  • 作者:
    Xinyun Zhang;Ying Yang;ShengSen Chen;Wenchao Li;Yong Li;Brian J. Akerley;Linyun Shao;Wenhong Zhang;Hao Shen;Michael C. Abt
  • 通讯作者:
    Michael C. Abt

Michael C. Abt的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael C. Abt', 18)}}的其他基金

Project 3: Defining adaptive immune interactions that shape Clostridioides difficile infection
项目 3:定义影响艰难梭菌感染的适应性免疫相互作用
  • 批准号:
    10625579
  • 财政年份:
    2023
  • 资助金额:
    $ 47.43万
  • 项目类别:
Investigating Immune-Microbiome interactions during treatment of Clostridioides difficile with fecal microbiome transplantation
研究粪便微生物组移植治疗艰难梭菌期间免疫-微生物组的相互作用
  • 批准号:
    10549862
  • 财政年份:
    2021
  • 资助金额:
    $ 47.43万
  • 项目类别:
Immune regulation of the transcriptional and spatial profile of Clostridioides difficile
艰难梭菌转录和空间谱的免疫调节
  • 批准号:
    10448396
  • 财政年份:
    2021
  • 资助金额:
    $ 47.43万
  • 项目类别:
Investigating Immune-Microbiome interactions during treatment of Clostridioides difficile with fecal microbiome transplantation
研究粪便微生物组移植治疗艰难梭菌期间免疫-微生物组的相互作用
  • 批准号:
    10343845
  • 财政年份:
    2021
  • 资助金额:
    $ 47.43万
  • 项目类别:
Immune regulation of the transcriptional and spatial profile of Clostridioides difficile
艰难梭菌转录和空间谱的免疫调节
  • 批准号:
    10288376
  • 财政年份:
    2021
  • 资助金额:
    $ 47.43万
  • 项目类别:
Treating chronic viral infection by epigenetic reprogramming of exhausted CD8 T cells
通过对耗尽的 CD8 T 细胞进行表观遗传重编程来治疗慢性病毒感染
  • 批准号:
    10242714
  • 财政年份:
    2017
  • 资助金额:
    $ 47.43万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 47.43万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 47.43万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 47.43万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 47.43万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 47.43万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 47.43万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 47.43万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 47.43万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 47.43万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 47.43万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了